stockrow10x Genomics
TXG Healthcare Medical Devices
10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.
- Revenue
- +1.12%
- EPS
- +31.8%
- Free cash flow
- −4.61%
Quarter to September 2026, against a year earlier
Follow TXG
Alert me
10x Genomics (TXG) Free cash flow margin
10x Genomics's free cash flow margin over the twelve months to 30 September 2026 was 15.2%, down 5.1 percentage points from fiscal 2025 (20.2%). Over the past ten years it has ranged from −85.8% (fiscal 2020) to 20.2% (fiscal 2025) — the current reading is the highest in ten years. That is above the Medical Devices industry median of −3.88% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 20.2% | 21.34 |
| FY2024 | −1.10% | 9.36 |
| FY2023 | −10.5% | 21.54 |
| FY2022 | −32.0% | (6.99) |
| FY2021 | −25.0% | 60.75 |
| FY2020 | −85.8% | (82.45) |
| FY2019 | −3.31% | 53.50 |
| FY2018 | −56.8% | (36.48) |
| FY2017 | −20.3% | — |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| HAE Haemonetics Corporation compare | 25.0% |
| GMED Globus Medical, Inc. compare | 24.4% |
| TXG 10x Genomics | 19.7% |
| BIO.B Bio-Rad Laboratories, Inc. compare | 18.1% |
| BIO Bio-Rad Laboratories, Inc. compare | 18.1% |
| PEN Penumbra, Inc. compare | 12.8% |
| PODD Insulet Corporation compare | 8.15% |
| BRKR Bruker Corporation compare | 6.97% |
| SNN Smith & Nephew SNATS, Inc. compare | 0.00% |
| Medical Devices industry median | −3.88% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on TXG
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement